Stay updated on Nivolumab in Resectable Osteosarcoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab in Resectable Osteosarcoma Clinical Trial page.

Latest updates to the Nivolumab in Resectable Osteosarcoma Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedAdministrative updates were made: a new revision (v3.4.2) and several date stamps were added. Older notices and some institutional references were removed, with no changes to the study data or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.7%

- Check21 days agoChange DetectedAdded a government funding lapse notice and updated the page revision to v3.4.1 (replacing v3.4.0).SummaryDifference0.4%

- Check28 days agoChange DetectedShow glossary option added and footer/metadata expanded with additional links and terminology (MeSH terms and related terms). Removed the No FEAR Act data note.SummaryDifference62%

- Check42 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4; the screenshots indicate only a metadata/version change with no substantive changes to study details or page content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check63 days agoChange DetectedIntroduced a consolidated Locations section listing participating states (Alabama, California, Colorado, Connecticut, Delaware, Florida, Kentucky, Maryland, New York, North Carolina, Ohio, Tennessee, Texas) and updated the page to revision v3.3.3, replacing the previous state-specific location blocks.SummaryDifference1%

- Check92 days agoChange DetectedRevision tag updated from v3.2.0 to v3.3.2 in the page footer.SummaryDifference0.0%

Stay in the know with updates to Nivolumab in Resectable Osteosarcoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab in Resectable Osteosarcoma Clinical Trial page.